Biolinerx Stock Filter Stocks by Fundamentals
| BLRX Stock | USD 0.75 0.07 8.54% |
BioLineRx fundamentals help investors to digest information that contributes to BioLineRx's financial success or failures. It also enables traders to predict the movement of BioLineRx Stock. The fundamental analysis module provides a way to measure BioLineRx's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioLineRx stock.
BioLineRx | Shares Owned by Institutions |
BioLineRx Current Valuation Drivers
We derive many important indicators used in calculating different scores of BioLineRx from analyzing BioLineRx's financial statements. These drivers represent accounts that assess BioLineRx's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of BioLineRx's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 22.0M | 42.5M | 90.2M | 30.4M | 100.8M | 105.9M | |
| Enterprise Value | 27.1M | 33.3M | 81.8M | 32.2M | 108.2M | 113.6M |
BioLineRx Institutional Holders
Institutional Holdings refers to the ownership stake in BioLineRx that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of BioLineRx's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing BioLineRx's value.| Shares | Rhumbline Advisers | 2024-03-31 | 18.3 K | Two Sigma Securities, Llc | 2024-03-31 | 17.3 K | Cutter & Co Brokerage, Inc. | 2024-03-31 | 16.7 K | Creative Planning Inc | 2023-12-31 | 14.6 K | Qube Research & Technologies | 2024-03-31 | 13.8 K | Ubs Group Ag | 2024-03-31 | 12.6 K | Cetera Investment Advisers | 2023-12-31 | 10.9 K | Goss Wealth Management Llc | 2024-03-31 | 4.3 K | Simplex Trading, Llc | 2024-03-31 | 2 K | Morgan Stanley - Brokerage Accounts | 2024-03-31 | 291.4 K | Susquehanna International Group, Llp | 2024-03-31 | 204.9 K |
BioLineRx Fundamentals
| Return On Equity | -1.89 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (2.47) % | ||||
| Current Valuation | 749.85 M | ||||
| Shares Outstanding | 79.94 M | ||||
| Shares Owned By Insiders | 8.54 % | ||||
| Shares Owned By Institutions | 1.75 % | ||||
| Number Of Shares Shorted | 219.07 K | ||||
| Price To Earning | (3.88) X | ||||
| Price To Book | 4.33 X | ||||
| Price To Sales | 11.94 X | ||||
| Revenue | 4.8 M | ||||
| EBITDA | (41.61 M) | ||||
| Net Income | (60.61 M) | ||||
| Cash And Equivalents | 43.15 M | ||||
| Cash Per Share | 0.90 X | ||||
| Total Debt | 11.59 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 4.58 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (22.61 M) | ||||
| Short Ratio | 0.68 X | ||||
| Earnings Per Share | (0.76) X | ||||
| Price To Earnings To Growth | 0.20 X | ||||
| Target Price | 13.75 | ||||
| Number Of Employees | 79 | ||||
| Beta | 0.92 | ||||
| Market Capitalization | 59.6 M | ||||
| Total Asset | 63.92 M | ||||
| Retained Earnings | (390.61 M) | ||||
| Working Capital | 16.33 M | ||||
| Current Asset | 48.18 M | ||||
| Current Liabilities | 3.14 M | ||||
| Net Asset | 63.92 M |
About BioLineRx Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioLineRx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLineRx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLineRx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BioLineRx offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioLineRx's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biolinerx Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biolinerx Stock:Check out BioLineRx Piotroski F Score and BioLineRx Altman Z Score analysis. For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for BioLineRx Stock analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is BioLineRx's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioLineRx. If investors know BioLineRx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioLineRx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.76) | Revenue Per Share 0.075 | Return On Assets (0.38) | Return On Equity (1.89) |
The market value of BioLineRx is measured differently than its book value, which is the value of BioLineRx that is recorded on the company's balance sheet. Investors also form their own opinion of BioLineRx's value that differs from its market value or its book value, called intrinsic value, which is BioLineRx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioLineRx's market value can be influenced by many factors that don't directly affect BioLineRx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioLineRx's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioLineRx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioLineRx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.